2型固有淋巴细胞在肝脏疾病免疫调控中的作用

韩静; 郭金波; 张晓岚

doi:10.3969/j.issn.1001-5256.2019.09.054

2型固有淋巴细胞在肝脏疾病免疫调控中的作用

DOI: 10.3969/j.issn.1001-5256.2019.09.054

河北医科大学第二医院东院区消化内科

基金项目:

河北省自然科学基金(H2018206363)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1090
- HTML全文浏览量: 16
- PDF下载量: 202
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-17
- 出版日期: 2019-09-20

Role of type 2 innate lymphoid cells in immunoregulation of liver diseases

Department of Gastroenterology, East Branch of The Second Hospital of Hebei Medical University

Research funding:

摘要

摘要: 固有淋巴细胞（ILCs）是新发现的一类固有免疫细胞,2型固有淋巴细胞（ILC2s）是其中一个细胞亚群,在受到IL-25、IL-33等刺激后可产生2型辅助型T淋巴细胞（Th2）因子,具有启动和维持2型免疫反应的作用。ILC2s属于固有免疫细胞,又具有调节适应性免疫的功能,参与炎症、组织修复、细胞增殖、代谢、调节免疫等病理生理过程。肝脏是人体重要的代谢器官和免疫器官,含有多种免疫细胞。ILC2s在肝脏疾病中具有调节免疫、调控炎症以及组织修复等重要作用。总结了ILC2s的生理功能及其在肝脏疾病发病机制中的免疫调控机制。
- 固有淋巴细胞 /
- 肝疾病 /
- 免疫,先天
Abstract: Innate lymphoid cells ( ILCs) are a new type of innate immune cells discovered in recent years, and type 2 ILCs ( ILC2 s) are a subset of ILCs and can produce type 2 T-helper cytokines after being activated by interleukin-25 and interleukin-33, which helps to start and maintain type 2 immune response. ILC2 s belong to innate immune cells and can regulate adaptive immunity and participate in various pathophysiological processes such as inflammation, tissue repair, cell proliferation, metabolism, and immunoregulation. The liver is recognized as an important metabolic and immune organ in the human body and contains several types of immune cells. ILC2 s can regulate immune response, inflammation, and tissue repair in liver diseases. This article summarizes the physiological function of ILC2 s and the immunomodulatory mechanism of ILC2 s in liver disease.
- innate lymphoid cells /
- liver diseases /
- immunity, innate

HTML全文

参考文献(43)

[1] ARTIS D, SPITS H. The biology of innate lymphoid cells[J].Nature, 2015, 517 (7534) :293-301.

[2] IGNACIO A, BREDA CNS, CAMARA NOS. Innate lymphoid cells in tissue homeostasis and diseases[J]. World J Hepatol, 2017, 9 (23) :979-989.

[3] FORT MM, CHEUNG J, YEN D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo[J]. Immunity, 2001, 15 (6) :985-995.

[4] FALLON PG, BALLANTYNE SJ, MANGAN NE, et al. Identification of an interleukin (IL) -25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion[J]. J Exp Med, 2006, 203 (4) :1105-1116.

[5] MORO K, YAMADA T, TANABE M, et al. Innate production of T (H) 2 cytokines by adipose tissue-associated c-Kit (+) Sca-1 (+) lymphoid cells[J]. Nature, 2010, 463 (7280) :540-544.

[6] PRICE AE, LIANG HE, SULLIVAN BM, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity[J].Proc Natl Acad Sci U S A, 2010, 107 (25) :11489-11494.

[7] SAENZ SA, SIRACUSA MC, PERRIGOUE JG, et al. IL25 elicits a multipotent progenitor cell population that promotes T (H) 2 cytokine responses[J]. Nature, 2010, 464 (7293) :1362-1366.

[8] NEILL DR, WONG SH, BELLOSI A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity[J]. Nature, 2010, 464 (7293) :1367-1370.

[9] SPITS H, ARTIS D, COLONNA M, et al. Innate lymphoid cells—a proposal for uniform nomenclature[J]. Nat Rev Immuno, 2013, 13 (2) :145-149.

[10] CONSTANTINIDES MG, McDONALD BD, VERHOEF PA, et al. A committed precursor to innate lymphoid cells[J]. Nature, 2014, 508 (7496) :397-401.

[11] SEILLET C, RANKIN LC, GROOM JR, et al. Nfil3 is required for the development of all innate lymphoid cell subsets[J]. J Exp Med, 2014, 211 (9) :1733-1740.

[12] CHERRIER M, SAWA S, EBERL G. Notch, Id2, and RORγt sequentially orchestrate the fetal development of lymphoid tissue inducer cells[J]. J Exp Med, 2012, 209 (4) :729-740.

[13] HOYLER T, KLOSE CS, SOUABNI A, et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells[J]. Immunity, 2012, 37 (4) :634-648.

[14] KLEIN WOLTERINK RG, SERAFINI N, van NIMWEGEN M, et al. Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5+and IL-13+type 2 innate lymphoid cells[J]. Proc Natl Acad Sci U S A, 2013, 110 (25) :10240-10245.

[15] HALIM TY, MACLAREN A, ROMANISH MT, et al. Retinoicacid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation[J]. Immunity, 2012, 37 (3) :463-474.

[16] SPOONER CJ, LESCH J, YAN D, et al. Specification of type2 innate lymphocytes by the transcriptional determinant Gfi1[J]. Nat Immunol, 2013, 14 (12) :1229-1236.

[17] YANG Q, MONTICELLI LA, SAENZ SA, et al. T cell factor 1 is required for group 2 innate lymphoid cell generation[J]. Immunity, 2013, 38 (4) :694-704.

[18] KIM HY, UMETSU DT, DEKRUYFF RH. Innate lymphoid cells in asthma:Will they take your breath away[J]. Eur J Immunol, 2016, 46 (4) :795-806.

[19] SUGITA K, STEER CA, MARTINEZ-GONZALEZ I, et al. Type 2innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients[J]. J Allergy Clin Immunol, 2018, 141 (1) :300-310. e11.

[20] SALIMI M, BARLOW JL, SAUNDERS SP, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis[J]. J Exp Med, 2013, 210 (13) :2939-2950.

[21] MONTICELLI LA, SONNENBERG GF, ABT MC, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus[J]. Nat Immunol, 2011, 12 (11) :1045-1054.

[22] LI J, RAZUMILAVA N, GORES GJ, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation[J]. J Clin Invest, 2014, 124 (7) :3241-3251.

[23] von MJ, JI M, LIANG HE, et al. Tuft-cell-derived IL-25regulates an intestinal ILC2-epithelial response circuit[J].Nature, 2016, 529 (7585) :221-225.

[24] LEE MW, ODEGAARD JI, MUKUNDAN L, et al. Activated type 2innate lymphoid cells regulate beige fat biogenesis[J]. Cel, 2015, 160 (1-2) :74-87.

[25] DALMAS E, LEHMANN FM, DROR E, et al. Interleukin-33-activated islet-resident innate lymphoid cells promote insulin secretion through myeloid cell retinoic acid production[J]. Immunity, 2017, 47 (5) :928-942. e7.

[26] LU P, JI X, WAN J, et al. Activity of group 2 innate lymphoid cells is associated with chronic inflammation and dysregulated metabolic homoeostasis in type 2 diabetic nephropathy[J].Scand J Immunol, 2018, 87 (2) :99-107.

[27] OLIPHANT CJ, HWANG YY, WALKER JA, et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4 (+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion[J]. Immunity, 2014, 41 (2) :283-295.

[28] MIRCHANDANI AS, BESNARD AG, YIP E, et al. Type 2 innate lymphoid cells drive CD4+Th2 cell responses[J]. J Immunol, 2014, 192 (5) :2442-2448.

[29] PENG MJ, YANG XF, WEI X, et al. Influence of hepatitis B virus infection on intrahepatic natural killer cells and innate lymphoid cell 22[J]. J Clin Hepatol, 2016, 32 (10) :1883-1887. (in Chinese) 彭梅娟, 杨晓飞, 魏欣, 等. HBV感染对肝脏自然杀伤细胞和固有淋巴样细胞22的影响[J].临床肝胆病杂志, 2016, 32 (10) :1883-1887.

[30] YANG Z, TANG T, WEI X, et al. Type 1 innate lymphoid cells contribute to the pathogenesis of chronic hepatitis B[J]. Innate Immun, 2015, 21 (6) :665-673.

[31] CAYROL C, GIRARD JP. IL-33:An alarmin cytokine with crucial roles in innate immunity, inflammation and allergy[J]. Curr Opin Immunol, 2014, 31:31-37.

[32] ESLAM M, GEORGE J. Genetic and epigenetic mechanisms of NASH[J]. Hepatol Int, 2016, 10 (3) :394-406.

[33] GAO Y, LIU Y, YANG M, et al. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis[J]. Oncotarget, 2016, 7 (23) :33649-33661.

[34] VASSEUR P, DION S, FILLIOL A, et al. Endogenous IL-33has no effect on the progression of fibrosis during experimental steatohepatitis[J]. Oncotarget, 2017, 8 (30) :48563-48574.

[35] GIESECK RL, WILSON MS, WYNN TA. Type 2 immunity in tissue repair and fibrosis[J]. Nat Rev Immunol, 2018, 18 (1) :62-76.

[36] McHEDLIDZE T, WALDNER M, ZOPF S, et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis[J]. Immunity, 2013, 39 (2) :357-371.

[37] TAN Z, LIU Q, JIANG R, et al. Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells[J]. Cell Mol Immunol, 2018, 15 (4) :388-398.

[38] VANNELLA KM, RAMALINGAM TR, BORTHWICK LA, et al.Combinatorial targeting of TSLP, IL-25, and IL-33 in type 2cytokine-driven inflammation and fibrosis[J]. Sci Transl Med, 2016, 8 (337) :337ra65.

[39] VOLAREVIC V, MITROVIC M, MILOVANOVIC M, et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis[J]. J Hepatol, 2012, 56 (1) :26-33.

[40] LI S, ZHU FX, ZHANG HB, et al. Pretreatment with interleukin-33 reduces warm hepatic ischemia/reperfusion injury in mice[J].Chin Med J (Engl) , 2013, 126 (10) :1855-1859.

[41] LIANG Y, JIE Z, HOU L, et al. IL-33 induces nuocytes and modulates liver injury in viral hepatitis[J]. J Immunol, 2013, 190 (11) :5666-5675.

[42] NEUMANN K, KARIMI K, MEINERS J, et al. A proinflammatory role of type 2 innate lymphoid cells in murine immune-mediated hepatitis[J]. J Immunol, 2017, 198 (1) :128-137.

[43] GWELA A, SIDDHANATHI P, CHAPMAN RW, et al. Th1 and innate lymphoid cells accumulate in primary sclerosing cholangitis-associated inflammatory bowel disease[J]. J Crohns Colitis, 2017, 11 (9) :1124-1134.

施引文献

资源附件(0)

访问统计